Halberd Corporation (OTC PINK:HALB) has made huge strides towards its groundbreaking nasal spray to combat Traumatic Brain Injury (TBI). After initial preclinical phase testing by Mississippi State University (MSU), the revolutionary spray has been proven to target antigens in cerebrospinal fluid, ultimately eliminating the irreversible effects of TBI. This is a massive breakthrough in the medical industry to assert greater security and safety for all.
MSU is confidently forging ahead with their project to develop a Halberd Nasal Spray to aid those suffering from Traumatic Brain Injury. With remarkable progress, they are now on the verge of completing the testing protocols for the second and third phases of trials. On this crucial milestone, the university is well on its way to revolutionizing the treatment of TBI.
In a pioneering research initiative, Michigan State University is developing and applying special tests to establish the relationship between the level of head impact sustained and the resultant severity of brain injury, something never done before.
This cutting-edge research will involve collecting data on head impact through special testing parameters and study endpoints. The findings of this study will then be used to guide the start of actual nasal spray testing.
Halberd’s nasal spray is a revolutionary blend of three active ingredients designed to protect the brain from irreversible damage if used within hours of a traumatic brain injury. MSU is currently running a pre-clinical model to document how this spray can significantly improve the outcome of brain trauma, recognizing the importance of timely application of the spray in controlling the inflammatory cytokines and neurotransmitters triggered by head trauma. Halberd’s Nasal Spray can be a game-changer in preventing long-term neurodegeneration.
Halberd, in collaboration with research partners Mississippi State University and Youngstown State University, is on a mission to address the growing concern of Traumatic Brain Injury in America with a revolutionary nasal spray solution! By identifying the primary trigger inflammatory cytokines and neurotransmitters in Cerebrospinal Fluid (CSF), Halberd is dedicated to creating an early treatment that can be easily self-administered to those who are affected by a traumatic brain injury event. With wide acceptance by both contact sports participants and military personnel, Halberd is certain to make a positive impact on the lives of those affected by traumatic brain injury.
If the MSU test results are positive, Halberd is on the cusp of realizing its first therapeutic product, a monumental breakthrough that can offer a much needed solution to the economic and humanitarian costs of TBI. With an estimated economic cost of $4.2 trillion – including $327 billion in medical care, $69 billion in work loss, and $3.8 trillion in value of statistical life and quality of life losses – there is a huge potential market for a product that proactively treats brain trauma through timely suppression of excess neurotransmitters and inflammatory cytokines. Such a product is unprecedented, and could be game-changing for treating this debilitating condition.